英矽智能再冲港交所：AI制药光环下的长跑者，能否跨越“死亡之谷”？

MoFo Shanghai Managing Partner Chuan Sun has been quoted in a recent article discussing the opportunities and challenges in the growing AI-driven pharmaceutical market.

According to Chuan, AI plays an important role in two aspects. First, it helps identify better targets during the drug discovery phase. Second, AI can be used to design clinical trial protocols, which are crucial for the success of clinical trials. Poorly designed protocols can lead to significant issues that can jeopardize the entire trial.

Chuan also emphasized the increasing prevalence of AI in market trading. “Before AI, designing clinical trial protocols was a highly time-consuming, labor-intensive, and costly process. However, the advantage of AI lies in its ability to leverage and process large volumes of data. As the amount of data grows, AI becomes even more effective in assisting protocol design.”

Read the full article.